Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2023 | Approaching lenalidomide-refractory multiple myeloma: unmet needs and ongoing trials

Luciano Costa • 13 May 2023
COMy 2023
Multiple Myeloma Antibodies Bortezomib CAR-T Ciltacabtagene autoleucel Daratumumab Dexamethasone Lenalidomide Pomalidomide
CARTITUDE-4

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some insights into the challenges with approaching patients with lenalidomide-refractory multiple myeloma, highlighting current treatment strategies for these patients. Dr Costa then goes on to discuss novel approaches being explored, drawing focus on the excitement surrounding the CARTITUDE-4 trial (NCT04181827). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Luciano Costa

CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma 4:04
CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma
Luciano Costa • 13 Dec 2024
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT 4:50
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT
Luciano Costa • 13 Dec 2024
Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3 3:24
Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3
Luciano Costa • 13 Dec 2024
Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy 3:01
Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy
Luciano Costa • 26 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals